文献速递核素与放射性配体治疗肿瘤 PET/CT

长效生长抑素类似物对[177Lu]Lu-HA-DOTATATE摄取的影响

The effect of long-acting somatostatin analogues on the uptake of [177Lu]Lu-HA-DOTATATE.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2023-01-04

本研究纳入接受7.4 GBq [177Lu]Lu-HA-DOTATATE治疗的神经内分泌肿瘤患者,比较继续使用长效奥曲肽或长效兰瑞肽与停用超过6周对照组的SPECT/CT摄取。结果显示肿瘤摄取在各组间无显著差异,但兰瑞肽组健康肝实质摄取显著降低,奥曲肽和兰瑞肽组脾脏摄取均显著降低。

要点

  • 长效奥曲肽和兰瑞肽不干扰肿瘤病灶对[177Lu]Lu-HA-DOTATATE的摄取。
  • 兰瑞肽给药后健康肝实质摄取显著降低,奥曲肽和兰瑞肽均使脾脏摄取显著降低。
  • 肾脏、骨髓和血池摄取在各组间无差异。

核心结论

  • 长效奥曲肽和兰瑞肽在注射后24小时不干扰肿瘤病灶对[177Lu]Lu-HA-DOTATATE的摄取。
  • 兰瑞肽给药后健康肝实质摄取显著降低,奥曲肽和兰瑞肽给药后健康脾脏摄取均显著降低。

研究设计与样本

  • 连续纳入接受7.4 GBq [177Lu]Lu-HA-DOTATATE治疗的神经内分泌肿瘤患者,共42例、135个治疗周期。
  • 分为3组:对照组(PRRT前停用LA-SSA超过6周,57个周期)、PRRT前6周内继续长效奥曲肽组(50个周期)、PRRT前6周内继续长效兰瑞肽组(28个周期)。
  • PRRT后24小时行SPECT/CT,定量健康组织(脾、肝、肾、骨髓)和肿瘤病灶的摄取。
  • 采用Mann-Whitney U检验比较长效奥曲肽组和长效兰瑞肽组与对照组的摄取差异。

主要发现

  • 兰瑞肽组肝实质摄取较对照组显著降低(p < 0.001)。
  • 奥曲肽组和兰瑞肽组脾脏摄取均较对照组显著降低(均p < 0.001)。
  • 肾脏、骨髓和血池摄取在各组间无差异。
  • 兰瑞肽组肿瘤摄取与对照组相同(p = 0.862),奥曲肽组肿瘤摄取与对照组相同(p = 0.201),与肿瘤位置无关。

关键数值与推荐

  • 根据IAEA/EANM/SNMMI指南,长效生长抑素类似物应在肽受体放射性核素治疗(PRRT)前4-6周停用,以防止生长抑素受体饱和。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: According to IAEA/EANM/SNMMI guidelines, long-acting somatostatin analogues (LA-SSAs) should be discontinued 4-6 weeks prior to peptide receptor radionuclide therapy (PRRT) to prevent somatostatin receptor saturation. The aim of this study was to determine the effect of continued use of long-acting SSAs during PRRT on the uptake of [177Lu]Lu-HA-DOTATATE on SPECT/CT. METHODS: Consecutive patients with neuroendocrine tumours who were treated with PRRT receiving 7.4 GBq of [177Lu]Lu-HA-DOTATATE were included. Patients were divided into 3 groups: (1) control (LA-SSA stopped > 6 weeks prior to PRRT), or continued treatment with (2) long-acting octreotide < 6 weeks prior to PRRT, or (3) long-acting lanreotide < 6 weeks prior to PRRT. The uptake of [177Lu]Lu-HA-DOTATATE was quantified in healthy tissues (spleen, liver, kidneys, bone marrow) and tumour lesions on SPECT/CT performed 24 h after PRRT. A Mann-Whitney U test was used to determine differences in uptake between the long-acting octreotide and long-acting lanreotide groups compared to the control group. RESULTS: Forty-two patients with 135 cycles of PRRT were included: 28 with lanreotide, 50 with octreotide, and 57 cycles without LA-SSAs. Uptake of [177Lu]Lu-HA-DOTATATE was significantly decreased in liver parenchyma in patients with lanreotide (p < 0.001) and in the spleen in patients with either octreotide or lanreotide (both p < 0.001). No differences were observed for uptake in kidneys, bone marrow, and blood pool. Uptake of [177Lu]Lu-HA-DOTATATE in tumours was the same in patients with lanreotide compared to the control (p = 0.862) and in patients with octreotide compared to the control (p = 0.201), independent of tumour location. CONCLUSION: Long-acting octreotide and lanreotide do not interfere with the uptake of [177Lu]Lu-HA-DOTATATE in tumour lesions 24 h post-injection. Uptake in healthy liver parenchyma significantly decreases after lanreotide administration prior to PRRT, while uptake in healthy spleen tissue significantly decreases with both octreotide and lanreotide administration.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Veerman CHAM, Siebinga H, de Vries-Huizing DMV, et al. The effect of long-acting somatostatin analogues on the uptake of [177Lu]Lu-HA-DOTATATE. Eur J Nucl Med Mol Imaging. 2023. PMID: 36598536. doi:10.1007/s00259-022-06094-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。